IVD Raw Material Market by Product Type (Proteins, Beads, Particles, Antibodies), Technology (Immunoassay, Hematology), Application (Infectious Disease, Diabetes), Supply Source, Origin (Biological, Synthetic), End User (CROs) - Global Forecast to 2031
The IVD raw material market is projected to grow from USD 21.5 billion in 2026 to USD 31.1 billion by 2031, growing at a CAGR of 7.7%. The increasing prevalence of chronic and infectious diseases, the rising demand for early and accurate disease diagnosis, and the expanding adoption of advanced diagnostic technologies. The growing use of molecular diagnostic techniques such as PCR, NGS, FISH, and LAMP is increasing demand for high-quality oligonucleotides, nucleic acids, enzymes, and other specialized raw materials. At the same time, the rapid expansion of point-of-care testing is driving the need for antibodies, antigens, membranes, labels, and detection materials used in rapid diagnostic assays. Furthermore, advancements in recombinant technologies, protein engineering, and assay development are improving the performance, sensitivity, and reliability of diagnostic tests. These innovations are enabling diagnostic manufacturers to develop more accurate and efficient testing solutions, thereby supporting the growth of the global IVD raw material market.
“The infectious disease testing segment is expected to account for the largest share of the IVD raw material market, by application, during the forecast period.”
Based on application, the IVD raw material market is segmented into infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women's health & fertility, genetic & rare disease testing, and others. The infectious disease testing segment accounts for the largest market share due to the high global burden of infectious diseases and the increasing demand for rapid, accurate, and large-scale diagnostic testing. Diagnostic manufacturers extensively use raw materials such as antibodies, antigens, enzymes, oligonucleotides, nucleic acids, and detection reagents to develop immunoassays, molecular diagnostic tests, and point-of-care testing solutions for detecting bacterial, viral, fungal, and parasitic infections. Additionally, growing investments in public health programs, increasing awareness of early disease diagnosis, and the continued adoption of advanced molecular diagnostic technologies are driving demand for high-quality IVD raw materials in infectious disease testing, making it the largest application segment of the market.
“The immunoassay segment has the largest market share in the IVD raw material market during the forecast period.”
The global IVD raw material market can be segmented by technology into immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others. Among these, the immunoassay segment accounted for the largest market share. Immunoassay-based diagnostics remain a fundamental component of routine disease testing due to their high sensitivity, specificity, cost-effectiveness, and broad application across infectious diseases, oncology, cardiac markers, autoimmune disorders, and hormone testing. The widespread adoption of immunoassay platforms has generated substantial demand for critical raw materials, including antibodies, antigens, proteins, enzymes, labels, and detection reagents. Furthermore, continuous advancements in assay development, increasing diagnostic testing volumes, growing demand for rapid and accurate diagnostic solutions, and the expansion of automated immunoassay analyzers are expected to support the continued adoption of immunoassay technologies, thereby driving demand for IVD raw materials worldwide.
“Asia Pacific: The fastest-growing market for IVD raw material from 2026 to 2031”
The global IVD raw material market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. The region's growth is driven by the increasing prevalence of chronic and infectious diseases, expanding healthcare infrastructure, rising investments in diagnostic technologies, and growing demand for early and accurate disease diagnosis. China is strengthening its domestic diagnostic manufacturing capabilities through healthcare modernization initiatives and increased investment in biotechnology and life sciences. India is witnessing significant growth in diagnostic testing volumes, supported by the expansion of clinical laboratories and molecular diagnostic facilities, as well as the adoption of point-of-care testing. Additionally, Japan's advanced healthcare system, aging population, and strong focus on precision medicine continue to drive demand for high-quality diagnostic assays and the raw materials required for their development. These factors are expected to support the rapid growth of the IVD raw material market across the Asia Pacific region during the forecast period.
The break-up of the profile of primary participants in the IVD raw market:
Research Coverage:
This research report categorizes the IVD raw material market by product type (antibodies, antigens & proteins, enzymes & substrates, oligonucleotides & nucleic acids, beads & particles, membranes, labels & detection materials, buffers & diluents, and others), by technology (immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others), by application (infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women's health & fertility, genetic & rare disease testing, and others), by supply source (in-house manufacturing [captive] and third-party supply [merchant]), by source/origin (biological/natural source, recombinant/synthetic, and others), by end user (IVD manufacturers, contract research organizations, academic & research institutes, pharmaceutical & biotech companies, and others), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the IVD raw material market. A detailed analysis of the key industry players has been conducted to provide insights into their business overview, product portfolios, key strategies such as acquisitions, partnerships, collaborations, capacity expansions, and product launches, as well as recent developments associated with the IVD raw material market. Competitive analysis of emerging companies and market participants within the IVD raw materials ecosystem is also covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD raw material market and the subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
“The infectious disease testing segment is expected to account for the largest share of the IVD raw material market, by application, during the forecast period.”
Based on application, the IVD raw material market is segmented into infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women's health & fertility, genetic & rare disease testing, and others. The infectious disease testing segment accounts for the largest market share due to the high global burden of infectious diseases and the increasing demand for rapid, accurate, and large-scale diagnostic testing. Diagnostic manufacturers extensively use raw materials such as antibodies, antigens, enzymes, oligonucleotides, nucleic acids, and detection reagents to develop immunoassays, molecular diagnostic tests, and point-of-care testing solutions for detecting bacterial, viral, fungal, and parasitic infections. Additionally, growing investments in public health programs, increasing awareness of early disease diagnosis, and the continued adoption of advanced molecular diagnostic technologies are driving demand for high-quality IVD raw materials in infectious disease testing, making it the largest application segment of the market.
“The immunoassay segment has the largest market share in the IVD raw material market during the forecast period.”
The global IVD raw material market can be segmented by technology into immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others. Among these, the immunoassay segment accounted for the largest market share. Immunoassay-based diagnostics remain a fundamental component of routine disease testing due to their high sensitivity, specificity, cost-effectiveness, and broad application across infectious diseases, oncology, cardiac markers, autoimmune disorders, and hormone testing. The widespread adoption of immunoassay platforms has generated substantial demand for critical raw materials, including antibodies, antigens, proteins, enzymes, labels, and detection reagents. Furthermore, continuous advancements in assay development, increasing diagnostic testing volumes, growing demand for rapid and accurate diagnostic solutions, and the expansion of automated immunoassay analyzers are expected to support the continued adoption of immunoassay technologies, thereby driving demand for IVD raw materials worldwide.
“Asia Pacific: The fastest-growing market for IVD raw material from 2026 to 2031”
The global IVD raw material market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. The region's growth is driven by the increasing prevalence of chronic and infectious diseases, expanding healthcare infrastructure, rising investments in diagnostic technologies, and growing demand for early and accurate disease diagnosis. China is strengthening its domestic diagnostic manufacturing capabilities through healthcare modernization initiatives and increased investment in biotechnology and life sciences. India is witnessing significant growth in diagnostic testing volumes, supported by the expansion of clinical laboratories and molecular diagnostic facilities, as well as the adoption of point-of-care testing. Additionally, Japan's advanced healthcare system, aging population, and strong focus on precision medicine continue to drive demand for high-quality diagnostic assays and the raw materials required for their development. These factors are expected to support the rapid growth of the IVD raw material market across the Asia Pacific region during the forecast period.
The break-up of the profile of primary participants in the IVD raw market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier - 30%
- By Designation: C-level Executives - 27%, Directors – 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa - 4%
Research Coverage:
This research report categorizes the IVD raw material market by product type (antibodies, antigens & proteins, enzymes & substrates, oligonucleotides & nucleic acids, beads & particles, membranes, labels & detection materials, buffers & diluents, and others), by technology (immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others), by application (infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women's health & fertility, genetic & rare disease testing, and others), by supply source (in-house manufacturing [captive] and third-party supply [merchant]), by source/origin (biological/natural source, recombinant/synthetic, and others), by end user (IVD manufacturers, contract research organizations, academic & research institutes, pharmaceutical & biotech companies, and others), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the IVD raw material market. A detailed analysis of the key industry players has been conducted to provide insights into their business overview, product portfolios, key strategies such as acquisitions, partnerships, collaborations, capacity expansions, and product launches, as well as recent developments associated with the IVD raw material market. Competitive analysis of emerging companies and market participants within the IVD raw materials ecosystem is also covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD raw material market and the subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, emergence of rapid point-of-care [POC] technologies and rising adoption of automated analyzers, and growing preference for personalized medicine), restraints (unfavorable reimbursement scenario, stringent regulatory requirements), opportunities (introduction of disease-specific biomarkers and tests, increasing significance of companion diagnostics, growth opportunities in developing countries, improvements in immunoassay diagnostic technologies, and the growing digitalization trend), and challenges (maintaining batch-to-batch consistency and quality of raw materials, and supply chain disruptions affecting the availability of critical biological and synthetic reagents) influencing the growth of the IVD raw material market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the IVD raw material market
- Market Development: Comprehensive information about lucrative markets—the report analyzes the IVD raw material market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the IVD raw material market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product portfolios of leading players such as Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Medix Biochemica (Finland), Bio-Techne Corporation (U.S.), and Fapon Biotech Inc. (China), among others
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 IVD RAW MATERIALS MARKET OVERVIEW
3.2 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2026 VS. 2031
3.3 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.4 IVD RAW MATERIALS MARKET, BY APPLICATION, 2026 VS. 2031
3.5 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2026 VS. 2031
3.6 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2026 VS. 2031
3.7 IVD RAW MATERIALS MARKET, BY END USER, 2026 VS. 2031
3.8 IVD RAW MATERIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising prevalence of chronic and infectious diseases
4.2.1.2 Growing adoption of personalized medicine and companion diagnostics
4.2.1.3 Increasing use of recombinant antibodies, proteins, and enzymes
4.2.1.4 Growing demand for raw materials supporting decentralized and rapid diagnostics
4.2.2 RESTRAINTS
4.2.2.1 High validation and quality-control costs
4.2.2.2 Long supplier qualification cycles
4.2.2.3 Limited availability of specialized biological raw materials
4.2.3 OPPORTUNITIES
4.2.3.1 Adoption of recombinant and animal-free raw materials
4.2.3.2 Localization of raw material manufacturing in emerging markets
4.2.3.3 Development of next-generation molecular diagnostic reagents
4.2.4 CHALLENGES
4.2.4.1 Maintaining batch-to-batch consistency
4.2.4.2 Building resilient supply chains for critical biological inputs
4.2.4.3 Meeting evolving IVDR/FDA supplier documentation requirements
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN IVD RAW MATERIALS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE, BY REGION, 2024–2026
5.6.2 AVERAGE SELLING PRICE, BY KEY PLAYER, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 300213)
5.7.2 EXPORT SCENARIO (HS CODE 300213)
5.8 KEY CONFERENCES & EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10 INVESTMENT & FUNDING SCENARIO
5.11 IMPACT OF US TARIFFS—IVD RAW MATERIALS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGIONS
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 OEM IVD manufacturers
5.11.5.2 Biopharmaceutical companies
5.11.5.3 CROs and research institutions
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 IMMUNOASSAY
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 MOLECULAR DIAGNOSTICS
6.3 TECHNOLOGY/PRODUCT ROADMAP
6.4 PATENT ANALYSIS
6.4.1 LIST OF KEY PATENTS
6.5 FUTURE APPLICATIONS
6.6 IMPACT OF AI/GENERATIVE AI ON IVD RAW MATERIALS MARKET
6.6.1 INTRODUCTION
6.6.2 TOP USE CASES AND MARKET POTENTIAL
6.6.3 KEY COMPANIES IMPLEMENTING AI
6.6.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY LANDSCAPE
7.1.1.1 North America
7.1.1.1.1 US
7.1.1.1.2 Canada
7.1.1.2 Europe
7.1.1.3 Asia Pacific
7.1.1.3.1 Japan
7.1.1.3.2 China
7.1.1.3.3 India
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN IVD RAW MATERIALS MARKET
7.2.1.1 Eco-friendly Initiatives
7.2.2 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE
9.1 INTRODUCTION
9.2 ANTIBODIES
9.2.1 MONOCLONAL ANTIBODIES
9.2.1.1 Increasing demand for highly specific and reproducible antibody reagents in immunoassay and rapid diagnostic applications to drive segment growth
9.2.2 POLYCLONAL ANTIBODIES
9.2.2.1 Broad target recognition and strong signal generation to sustain demand for polyclonal antibodies in diagnostic assays
9.2.3 RECOMBINANT ANTIBODIES
9.2.3.1 Growing adoption of engineered antibodies to improve consistency, scalability, and performance of IVD assays
9.3 ANTIGENS & PROTEINS
9.3.1 RECOMBINANT ANTIGENS
9.3.1.1 Growing preference for scalable and consistent antigen production to support increasing IVD assay demand
9.3.2 NATIVE PROTEINS
9.3.2.1 Continued demand for biologically authentic proteins in sensitive assay development and clinically representative IVD applications
9.3.3 CALIBRATORS & STANDARDS
9.3.3.1 Increasing emphasis on assay standardization and traceability to drive demand for calibrators & reference materials
9.4 ENZYMES & SUBSTRATES
9.4.1 DETECTION ENZYMES
9.4.1.1 Increasing adoption of enzyme-based signal generation to improve sensitivity and quantitative performance of immunoassays
9.4.2 AMPLIFICATION ENZYMES
9.4.2.1 Growing adoption of molecular diagnostic testing to accelerate demand for high-performance amplification enzymes
9.4.3 SUBSTRATES & COENZYMES
9.4.3.1 Increasing need for optimized reaction components to enhance enzyme activity and diagnostic assay signal generation
9.5 OLIGONUCLEOTIDES & NUCLEIC ACIDS
9.5.1 PRIMERS & PROBES
9.5.1.1 Increasing adoption of PCR and multiplex molecular assays to drive demand for sequence-specific primers and probes
9.5.2 SYNTHETIC DNA/RNA
9.5.2.1 Growing use of synthetic DNA and RNA sequences to accelerate molecular assay development and validation
9.6 BEADS & PARTICLES
9.6.1 MAGNETIC BEADS
9.6.1.1 Growing adoption of automated magnetic-particle immunoassays to drive demand for high-performance magnetic beads
9.6.2 LATEX BEADS
9.6.2.1 Widespread use of latex particle-based agglutination and turbidimetric assays to sustain demand for latex beads
9.6.3 GOLD NANOPARTICLES
9.6.3.1 Increasing adoption of gold nanoparticle-based signal generation in rapid and visually readable diagnostic assays
9.7 MEMBRANES
9.7.1 NITROCELLULOSE MEMBRANES
9.7.1.1 High protein-binding capacity and controlled capillary flow to underpin nitrocellulose use across lateral flow and membrane-based immunodiagnostics
9.7.2 NYLON & PVDF MEMBRANES
9.7.2.1 Higher chemical resistance and specialized biomolecule immobilization requirements to sustain demand
9.7.3 GLASS FIBER PADS
9.7.3.1 Consistent sample and conjugate transport to strengthen role of glass fiber pads in lateral flow test construction
9.8 LABELS & DETECTION MATERIALS
9.8.1 FLUORESCENT DYES
9.8.1.1 Higher analytical sensitivity and instrument-based quantification to expand use of fluorescent detection in IVD
9.8.2 CHEMILUMINESCENT LABELS
9.8.2.1 Demand for ultra-sensitive immunoassays to sustain adoption of chemiluminescent labels
9.8.3 COLLOIDAL GOLD CONJUGATES
9.8.3.1 Established visual-readout capability and simplicity of lateral flow testing to sustain demand for colloidal gold conjugates
9.9 BUFFERS & DILUENTS
9.9.1 GREATER EMPHASIS ON REACTION STABILITY AND INTERFERENCE CONTROL TO SUPPORT RELIABLE IVD ASSAY PERFORMANCE
9.10 OTHER PRODUCTS
10 IVD RAW MATERIALS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 IMMUNOASSAY
10.2.1 INCREASING ADOPTION OF HIGH-SENSITIVITY, AUTOMATED IMMUNOASSAYS TO SUSTAIN DEMAND FOR RAW MATERIALS
10.3 MOLECULAR DIAGNOSTICS
10.3.1 EXPANSION OF PCR AND ISOTHERMAL AMPLIFICATION FORMATS TO INCREASE DEMAND FOR ENGINEERED POLYMERASES, MASTER MIXES, OLIGONUCLEOTIDES, AND NUCLEIC ACID CONTROLS
10.4 CLINICAL CHEMISTRY
10.4.1 INCREASING DEMAND FOR HIGH-QUALITY ENZYMES, PROTEINS, LIPOPROTEINS, AND REFERENCE MATERIALS TO SUPPORT AUTOMATED QUANTITATIVE TESTING
10.5 HEMATOLOGY
10.5.1 GROWING DEMAND FOR CELL-BASED REFERENCE MATERIALS AND BLOOD-DERIVED COMPONENTS TO STRENGTHEN RAW-MATERIAL REQUIREMENTS FOR HEMATOLOGY DIAGNOSTICS
10.6 MICROBIOLOGY & CULTURE
10.6.1 ADVANCES IN CULTURE-MEDIA FORMULATION AND MICROBIAL IDENTIFICATION TO STRENGTHEN DEMAND FOR SPECIALIZED MICROBIOLOGY RAW MATERIALS
10.7 COAGULATION TESTING
10.7.1 GREATER EMPHASIS ON FAST, STANDARDIZED MEASUREMENT OF CLOTTING AND FIBRINOLYSIS TO SHAPE RAW MATERIAL REQUIREMENTS IN COAGULATION DIAGNOSTICS
10.8 FLOW CYTOMETRY
10.8.1 MULTIPARAMETER CELLULAR ANALYSIS TO INCREASE DEMAND FOR HIGHLY SPECIFIC ANTIBODIES AND FLUORESCENT DETECTION MATERIALS
10.9 OTHER TECHNOLOGIES
11 IVD RAW MATERIALS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 INFECTIOUS DISEASES
11.2.1 BROAD PATHOGEN COVERAGE AND FREQUENT DEMAND FOR RAPID, SENSITIVE TESTING TO DRIVE MARKET GROWTH
11.3 ONCOLOGY/CANCER MARKERS
11.3.1 MOLECULAR EXPANSION OF BIOMARKER-BASED CANCER DETECTION AND MONITORING TO INCREASE DEMAND FOR RAW MATERIALS
11.4 CARDIAC MARKERS
11.4.1 HIGH DISEASE PREVALENCE AND USE OF HIGH-SENSITIVITY BIOMARKERS TO STRENGTHEN DEMAND FOR CARDIAC-MARKER RAW MATERIALS
11.5 DIABETES & METABOLIC DISORDERS
11.5.1 EXPANDING BIOMARKER-BASED SCREENING TO SUSTAIN DEMAND FOR HBA1C, INSULIN, GLUCOSE, AND RELATED IVD RAW MATERIALS
11.6 AUTOIMMUNE DISEASES
11.6.1 GROWING RELIANCE ON AUTOANTIBODY-BASED TESTING TO SUPPORT DIAGNOSIS OF DIVERSE AUTOIMMUNE CONDITIONS AND EXPAND DEMAND FOR HIGHLY SPECIFIC IVD RAW MATERIALS
11.7 BLOOD SCREENING
11.7.1 MANDATORY SCREENING OF DONATED BLOOD AND NEED TO DETECT MULTIPLE TRANSFUSION-TRANSMISSIBLE INFECTIONS UNDERPIN DEMAND FOR DIVERSE IVD RAW MATERIALS
11.8 WOMEN’S HEALTH & FERTILITY
11.8.1 HIGH PREVALENCE OF INFERTILITY AND EXPANDING HORMONE-BASED REPRODUCTIVE TESTING TO SUSTAIN THE DEMAND
11.9 GENETIC & RARE DISEASE TESTING
11.9.1 EXPANSION OF MOLECULAR AND GENETIC TESTING TO ADDRESS A LARGE AND CLINICALLY DIVERSE POPULATION
11.10 OTHER APPLICATIONS
12 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE
12.1 INTRODUCTION
12.2 IN-HOUSE MANUFACTURING
12.2.1 GREATER CONTROL OVER CRITICAL REAGENTS AND ASSAY PERFORMANCE TO SUSTAIN IN-HOUSE PRODUCTION
12.3 THIRD-PARTY SUPPLY
12.3.1 OUTSOURCING SPECIALIZED CAPABILITIES TO IMPROVE FLEXIBILITY AND ACCELERATE IVD DEVELOPMENT
13 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN
13.1 INTRODUCTION
13.2 BIOLOGICAL/NATURAL SOURCES
13.2.1 ANIMAL-DERIVED
13.2.1.1 Established assay performance and broad availability to sustain use of animal-derived IVD raw materials
13.2.2 HUMAN-DERIVED
13.2.2.1 Clinical relevance and patient-like matrices to sustain demand for human-derived IVD raw materials
13.3 RECOMBINANT/SYNTHETIC SOURCES
13.3.1 E. COLI-EXPRESSED
13.3.1.1 Scalable production and strong suitability for non-glycosylated proteins to support E. coli-based recombinant IVD materials
13.3.2 CHO-EXPRESSED
13.3.2.1 Mammalian expression for structurally complex biomarkers to improve assay relevance and performance
13.3.3 CHEMICALLY SYNTHESIZED
13.3.3.1 Precisely defined composition and scalable manufacturing to expand the role of synthetic materials in IVD
13.4 OTHER SOURCES
14 IVD RAW MATERIALS MARKET, BY END USER
14.1 INTRODUCTION
14.2 IVD MANUFACTURERS
14.2.1 EXPANDING ASSAY PORTFOLIOS AND TIGHTER CONTROL OF CRITICAL COMPONENTS TO DRIVE RAW-MATERIAL CONSUMPTION
14.3 CONTRACT RESEARCH ORGANIZATIONS
14.3.1 INCREASING OUTSOURCING OF ASSAY DEVELOPMENT AND VALIDATION TO ACCELERATE IVD COMMERCIALIZATION
14.4 ACADEMIC & RESEARCH INSTITUTES
14.4.1 GROWING TRANSLATIONAL RESEARCH AND ASSAY DEVELOPMENT TO EXPAND CONSUMPTION OF SPECIALIZED IVD RAW MATERIALS
14.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.5.1 INTEGRATION OF DIAGNOSTICS INTO DRUG DEVELOPMENT TO INCREASE DEMAND FOR BIOMARKER AND ASSAY COMPONENTS
14.6 OTHER END USERS
15 IVD RAW MATERIALS MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 US
15.2.1.1 Increasing demand for advanced diagnostics and a mature reimbursement framework to drive market
15.2.2 CANADA
15.2.2.1 Rising disease prevalence and demand for early diagnoses drive market growth
15.3 EUROPE
15.3.1 GERMANY
15.3.1.1 Increasing investments in life sciences and advanced diagnostics to propel demand for IVD raw materials
15.3.2 UK
15.3.2.1 Rising adoption of genomic testing and advanced diagnostics to support demand growth
15.3.3 FRANCE
15.3.3.1 High healthcare expenditure and continued investment in genomic medicine to drive market
15.3.4 ITALY
15.3.4.1 Growing geriatric population and increasing burden of chronic diseases to boost demand for IVD raw materials
15.3.5 SPAIN
15.3.5.1 Increasing adoption of genomic testing and advanced diagnostics to support the market
15.3.6 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 CHINA
15.4.1.1 Growing focus on preventive care and localization of IVD raw materials to boost market
15.4.2 JAPAN
15.4.2.1 Increasing research investment and adoption of advanced diagnostics to support market growth
15.4.3 INDIA
15.4.3.1 Rising incidence of diabetes and cancer and increasing localization of IVD manufacturing to augment growth
15.4.4 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 INCREASING HEALTHCARE INVESTMENT, DISEASE BURDEN, AND EXPANSION OF DIAGNOSTIC ACCESS TO SUPPORT MARKET GROWTH
15.6 MIDDLE EAST & AFRICA
15.6.1 INCREASING HEALTHCARE INVESTMENT, PREVENTIVE SCREENING, AND DIAGNOSTIC INFRASTRUCTURE TO SUPPORT MARKET GROWTH
16 IVD RAW MATERIALS MARKET: VOLUME ANALYSIS
16.1 INTRODUCTION
16.2 GLOBAL: NAT BASED PCR EQUIPMENT SOLD, 2024–2031 (THOUSAND UNITS)
17 COMPETITIVE LANDSCAPE
17.1 INTRODUCTION
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN IVD RAW MATERIALS MARKET
17.3 REVENUE ANALYSIS, 2023–2025
17.4 MARKET SHARE ANALYSIS, 2025
17.4.1 THIRD-PARTY SUPPLIERS MARKET SHARE ANALYSIS, 2025
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
17.5.1 STARS
17.5.2 EMERGING LEADERS
17.5.3 PERVASIVE PLAYERS
17.5.4 PARTICIPANTS
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
17.5.5.1 Company footprint
17.5.5.2 Region footprint
17.5.5.3 Product type footprint
17.5.5.4 End-user footprint
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.6.1 PROGRESSIVE COMPANIES
17.6.2 RESPONSIVE COMPANIES
17.6.3 DYNAMIC COMPANIES
17.6.4 STARTING BLOCKS
17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.6.5.1 Detailed list of key startups/SMEs
17.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
17.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
17.7 COMPANY VALUATION & FINANCIAL METRICS
17.7.1 FINANCIAL METRICS
17.7.2 COMPANY VALUATION
17.8 BRAND/PRODUCT COMPARISON
17.9 COMPETITIVE SCENARIO
17.9.1 PRODUCT LAUNCHES & APPROVALS
17.9.2 DEALS
18 COMPANY PROFILES
18.1 KEY PLAYERS
18.1.1 MERCK KGAA
18.1.1.1 Business overview
18.1.1.2 Products offered
18.1.1.3 Recent developments
18.1.1.3.1 Product launches & approvals
18.1.1.3.2 Deals
18.1.1.4 MnM view
18.1.1.4.1 Key strengths
18.1.1.4.2 Strategic choices
18.1.1.4.3 Weaknesses and competitive threats
18.1.2 THERMO FISHER SCIENTIFIC
18.1.2.1 Business overview
18.1.2.2 Products offered
18.1.2.3 Recent developments
18.1.2.3.1 Product enhancements
18.1.2.3.2 Deals
18.1.2.4 MnM view
18.1.2.4.1 Key strengths
18.1.2.4.2 Strategic choices
18.1.2.4.3 Weaknesses & competitive threats
18.1.3 BIO-TECHNE CORPORATION
18.1.3.1 Business overview
18.1.3.2 Products & services offered
18.1.3.3 Recent developments
18.1.3.3.1 Product launches & approvals
18.1.3.3.2 Deals
18.1.3.4 MnM view
18.1.3.4.1 Key strengths
18.1.3.4.2 Strategic choices
18.1.3.4.3 Weaknesses & competitive threats
18.1.4 FAPON BIOTECH
18.1.4.1 Business overview
18.1.4.2 Products & services offered
18.1.4.3 Recent developments
18.1.4.3.1 Product launches & approvals
18.1.4.4 MnM view
18.1.4.4.1 Key strengths
18.1.4.4.2 Strategic choices
18.1.4.4.3 Weaknesses & competitive threats
18.1.5 MERIDIAN BIOSCIENCE
18.1.5.1 Business overview
18.1.5.2 Products offered
18.1.5.3 Recent developments
18.1.5.3.1 Product launches
18.1.5.3.2 Deals
18.1.5.4 MnM view
18.1.5.4.1 Key strengths
18.1.5.4.2 Strategic choices
18.1.5.4.3 Weaknesses & competitive threats
18.1.6 MEDIX BIOCHEMICA
18.1.6.1 Business overview
18.1.6.2 Products & services offered
18.1.6.3 Recent developments
18.1.6.3.1 Deals
18.1.6.3.2 Expansions
18.1.7 ROCHE CUSTOMBIOTECH
18.1.7.1 Business overview
18.1.7.2 Products & services offered
18.1.8 DANAHER CORPORATION
18.1.8.1 Business overview
18.1.8.2 Products & services offered
18.1.8.3 Recent developments
18.1.8.3.1 Deals
18.1.9 SARTORIUS AG
18.1.9.1 Business overview
18.1.9.2 Products offered
18.1.10 HYTEST LTD.
18.1.10.1 Business overview
18.1.10.2 Products offered
18.1.11 TOYOBO CO., LTD.
18.1.11.1 Business overview
18.1.11.2 Products offered
18.1.12 LGC BIOSEARCH TECHNOLOGIES
18.1.12.1 Business overview
18.1.12.2 Products offered
18.2 OTHER PLAYERS
18.2.1 BBI SOLUTIONS
18.2.2 SURMODICS IVD
18.2.3 AHLSTROM OYJ
18.2.4 BANGS LABORATORIES
18.2.5 SCRIPPS LABORATORIES, INC.
18.2.6 MIKROGEN GMBH
18.2.7 ADVANCED MICRODEVICES PVT. LTD.
18.2.8 SEKISUI DIAGNOSTICS
18.2.9 RANDOX LABORATORIES LTD.
18.2.10 HIMEDIA LABORATORIES
18.2.11 SINO BIOLOGICAL
18.2.12 BIOSYNTH
18.2.13 NEW ENGLAND BIOLABS, INC.
19 RESEARCH METHODOLOGY
19.1 RESEARCH DATA
19.2 SECONDARY DATA
19.2.1 LIST OF SECONDARY SOURCES
19.2.2 PRIMARY DATA
19.2.2.1 Key data from primary sources
19.2.2.2 Breakdown of primary interviews
19.3 MARKET SIZE ESTIMATION
19.3.1 TOTAL MARKET SIZE: IVD RAW MATERIALS MARKET
19.3.2 BOTTOM-UP APPROACH
19.3.2.1 Approach 2: Study of annual reports and investor presentations
19.3.2.2 Approach 3: Primary interviews
19.3.2.3 Growth forecast
19.3.3 TOP-DOWN APPROACH
19.4 DATA TRIANGULATION
19.5 RESEARCH ASSUMPTIONS
19.5.1 STUDY-RELATED ASSUMPTIONS
19.6 STUDY ASSUMPTIONS
19.6.1 GROWTH RATE ASSUMPTIONS
19.7 RESEARCH LIMITATIONS
19.8 RISK ASSESSMENT
20 APPENDIX
20.1 DISCUSSION GUIDE
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3 CUSTOMIZATION OPTIONS
20.4 RELATED REPORTS
20.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 IVD RAW MATERIALS MARKET OVERVIEW
3.2 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2026 VS. 2031
3.3 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.4 IVD RAW MATERIALS MARKET, BY APPLICATION, 2026 VS. 2031
3.5 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2026 VS. 2031
3.6 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2026 VS. 2031
3.7 IVD RAW MATERIALS MARKET, BY END USER, 2026 VS. 2031
3.8 IVD RAW MATERIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising prevalence of chronic and infectious diseases
4.2.1.2 Growing adoption of personalized medicine and companion diagnostics
4.2.1.3 Increasing use of recombinant antibodies, proteins, and enzymes
4.2.1.4 Growing demand for raw materials supporting decentralized and rapid diagnostics
4.2.2 RESTRAINTS
4.2.2.1 High validation and quality-control costs
4.2.2.2 Long supplier qualification cycles
4.2.2.3 Limited availability of specialized biological raw materials
4.2.3 OPPORTUNITIES
4.2.3.1 Adoption of recombinant and animal-free raw materials
4.2.3.2 Localization of raw material manufacturing in emerging markets
4.2.3.3 Development of next-generation molecular diagnostic reagents
4.2.4 CHALLENGES
4.2.4.1 Maintaining batch-to-batch consistency
4.2.4.2 Building resilient supply chains for critical biological inputs
4.2.4.3 Meeting evolving IVDR/FDA supplier documentation requirements
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN IVD RAW MATERIALS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE, BY REGION, 2024–2026
5.6.2 AVERAGE SELLING PRICE, BY KEY PLAYER, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 300213)
5.7.2 EXPORT SCENARIO (HS CODE 300213)
5.8 KEY CONFERENCES & EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10 INVESTMENT & FUNDING SCENARIO
5.11 IMPACT OF US TARIFFS—IVD RAW MATERIALS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGIONS
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 OEM IVD manufacturers
5.11.5.2 Biopharmaceutical companies
5.11.5.3 CROs and research institutions
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 IMMUNOASSAY
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 MOLECULAR DIAGNOSTICS
6.3 TECHNOLOGY/PRODUCT ROADMAP
6.4 PATENT ANALYSIS
6.4.1 LIST OF KEY PATENTS
6.5 FUTURE APPLICATIONS
6.6 IMPACT OF AI/GENERATIVE AI ON IVD RAW MATERIALS MARKET
6.6.1 INTRODUCTION
6.6.2 TOP USE CASES AND MARKET POTENTIAL
6.6.3 KEY COMPANIES IMPLEMENTING AI
6.6.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY LANDSCAPE
7.1.1.1 North America
7.1.1.1.1 US
7.1.1.1.2 Canada
7.1.1.2 Europe
7.1.1.3 Asia Pacific
7.1.1.3.1 Japan
7.1.1.3.2 China
7.1.1.3.3 India
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN IVD RAW MATERIALS MARKET
7.2.1.1 Eco-friendly Initiatives
7.2.2 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE
9.1 INTRODUCTION
9.2 ANTIBODIES
9.2.1 MONOCLONAL ANTIBODIES
9.2.1.1 Increasing demand for highly specific and reproducible antibody reagents in immunoassay and rapid diagnostic applications to drive segment growth
9.2.2 POLYCLONAL ANTIBODIES
9.2.2.1 Broad target recognition and strong signal generation to sustain demand for polyclonal antibodies in diagnostic assays
9.2.3 RECOMBINANT ANTIBODIES
9.2.3.1 Growing adoption of engineered antibodies to improve consistency, scalability, and performance of IVD assays
9.3 ANTIGENS & PROTEINS
9.3.1 RECOMBINANT ANTIGENS
9.3.1.1 Growing preference for scalable and consistent antigen production to support increasing IVD assay demand
9.3.2 NATIVE PROTEINS
9.3.2.1 Continued demand for biologically authentic proteins in sensitive assay development and clinically representative IVD applications
9.3.3 CALIBRATORS & STANDARDS
9.3.3.1 Increasing emphasis on assay standardization and traceability to drive demand for calibrators & reference materials
9.4 ENZYMES & SUBSTRATES
9.4.1 DETECTION ENZYMES
9.4.1.1 Increasing adoption of enzyme-based signal generation to improve sensitivity and quantitative performance of immunoassays
9.4.2 AMPLIFICATION ENZYMES
9.4.2.1 Growing adoption of molecular diagnostic testing to accelerate demand for high-performance amplification enzymes
9.4.3 SUBSTRATES & COENZYMES
9.4.3.1 Increasing need for optimized reaction components to enhance enzyme activity and diagnostic assay signal generation
9.5 OLIGONUCLEOTIDES & NUCLEIC ACIDS
9.5.1 PRIMERS & PROBES
9.5.1.1 Increasing adoption of PCR and multiplex molecular assays to drive demand for sequence-specific primers and probes
9.5.2 SYNTHETIC DNA/RNA
9.5.2.1 Growing use of synthetic DNA and RNA sequences to accelerate molecular assay development and validation
9.6 BEADS & PARTICLES
9.6.1 MAGNETIC BEADS
9.6.1.1 Growing adoption of automated magnetic-particle immunoassays to drive demand for high-performance magnetic beads
9.6.2 LATEX BEADS
9.6.2.1 Widespread use of latex particle-based agglutination and turbidimetric assays to sustain demand for latex beads
9.6.3 GOLD NANOPARTICLES
9.6.3.1 Increasing adoption of gold nanoparticle-based signal generation in rapid and visually readable diagnostic assays
9.7 MEMBRANES
9.7.1 NITROCELLULOSE MEMBRANES
9.7.1.1 High protein-binding capacity and controlled capillary flow to underpin nitrocellulose use across lateral flow and membrane-based immunodiagnostics
9.7.2 NYLON & PVDF MEMBRANES
9.7.2.1 Higher chemical resistance and specialized biomolecule immobilization requirements to sustain demand
9.7.3 GLASS FIBER PADS
9.7.3.1 Consistent sample and conjugate transport to strengthen role of glass fiber pads in lateral flow test construction
9.8 LABELS & DETECTION MATERIALS
9.8.1 FLUORESCENT DYES
9.8.1.1 Higher analytical sensitivity and instrument-based quantification to expand use of fluorescent detection in IVD
9.8.2 CHEMILUMINESCENT LABELS
9.8.2.1 Demand for ultra-sensitive immunoassays to sustain adoption of chemiluminescent labels
9.8.3 COLLOIDAL GOLD CONJUGATES
9.8.3.1 Established visual-readout capability and simplicity of lateral flow testing to sustain demand for colloidal gold conjugates
9.9 BUFFERS & DILUENTS
9.9.1 GREATER EMPHASIS ON REACTION STABILITY AND INTERFERENCE CONTROL TO SUPPORT RELIABLE IVD ASSAY PERFORMANCE
9.10 OTHER PRODUCTS
10 IVD RAW MATERIALS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 IMMUNOASSAY
10.2.1 INCREASING ADOPTION OF HIGH-SENSITIVITY, AUTOMATED IMMUNOASSAYS TO SUSTAIN DEMAND FOR RAW MATERIALS
10.3 MOLECULAR DIAGNOSTICS
10.3.1 EXPANSION OF PCR AND ISOTHERMAL AMPLIFICATION FORMATS TO INCREASE DEMAND FOR ENGINEERED POLYMERASES, MASTER MIXES, OLIGONUCLEOTIDES, AND NUCLEIC ACID CONTROLS
10.4 CLINICAL CHEMISTRY
10.4.1 INCREASING DEMAND FOR HIGH-QUALITY ENZYMES, PROTEINS, LIPOPROTEINS, AND REFERENCE MATERIALS TO SUPPORT AUTOMATED QUANTITATIVE TESTING
10.5 HEMATOLOGY
10.5.1 GROWING DEMAND FOR CELL-BASED REFERENCE MATERIALS AND BLOOD-DERIVED COMPONENTS TO STRENGTHEN RAW-MATERIAL REQUIREMENTS FOR HEMATOLOGY DIAGNOSTICS
10.6 MICROBIOLOGY & CULTURE
10.6.1 ADVANCES IN CULTURE-MEDIA FORMULATION AND MICROBIAL IDENTIFICATION TO STRENGTHEN DEMAND FOR SPECIALIZED MICROBIOLOGY RAW MATERIALS
10.7 COAGULATION TESTING
10.7.1 GREATER EMPHASIS ON FAST, STANDARDIZED MEASUREMENT OF CLOTTING AND FIBRINOLYSIS TO SHAPE RAW MATERIAL REQUIREMENTS IN COAGULATION DIAGNOSTICS
10.8 FLOW CYTOMETRY
10.8.1 MULTIPARAMETER CELLULAR ANALYSIS TO INCREASE DEMAND FOR HIGHLY SPECIFIC ANTIBODIES AND FLUORESCENT DETECTION MATERIALS
10.9 OTHER TECHNOLOGIES
11 IVD RAW MATERIALS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 INFECTIOUS DISEASES
11.2.1 BROAD PATHOGEN COVERAGE AND FREQUENT DEMAND FOR RAPID, SENSITIVE TESTING TO DRIVE MARKET GROWTH
11.3 ONCOLOGY/CANCER MARKERS
11.3.1 MOLECULAR EXPANSION OF BIOMARKER-BASED CANCER DETECTION AND MONITORING TO INCREASE DEMAND FOR RAW MATERIALS
11.4 CARDIAC MARKERS
11.4.1 HIGH DISEASE PREVALENCE AND USE OF HIGH-SENSITIVITY BIOMARKERS TO STRENGTHEN DEMAND FOR CARDIAC-MARKER RAW MATERIALS
11.5 DIABETES & METABOLIC DISORDERS
11.5.1 EXPANDING BIOMARKER-BASED SCREENING TO SUSTAIN DEMAND FOR HBA1C, INSULIN, GLUCOSE, AND RELATED IVD RAW MATERIALS
11.6 AUTOIMMUNE DISEASES
11.6.1 GROWING RELIANCE ON AUTOANTIBODY-BASED TESTING TO SUPPORT DIAGNOSIS OF DIVERSE AUTOIMMUNE CONDITIONS AND EXPAND DEMAND FOR HIGHLY SPECIFIC IVD RAW MATERIALS
11.7 BLOOD SCREENING
11.7.1 MANDATORY SCREENING OF DONATED BLOOD AND NEED TO DETECT MULTIPLE TRANSFUSION-TRANSMISSIBLE INFECTIONS UNDERPIN DEMAND FOR DIVERSE IVD RAW MATERIALS
11.8 WOMEN’S HEALTH & FERTILITY
11.8.1 HIGH PREVALENCE OF INFERTILITY AND EXPANDING HORMONE-BASED REPRODUCTIVE TESTING TO SUSTAIN THE DEMAND
11.9 GENETIC & RARE DISEASE TESTING
11.9.1 EXPANSION OF MOLECULAR AND GENETIC TESTING TO ADDRESS A LARGE AND CLINICALLY DIVERSE POPULATION
11.10 OTHER APPLICATIONS
12 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE
12.1 INTRODUCTION
12.2 IN-HOUSE MANUFACTURING
12.2.1 GREATER CONTROL OVER CRITICAL REAGENTS AND ASSAY PERFORMANCE TO SUSTAIN IN-HOUSE PRODUCTION
12.3 THIRD-PARTY SUPPLY
12.3.1 OUTSOURCING SPECIALIZED CAPABILITIES TO IMPROVE FLEXIBILITY AND ACCELERATE IVD DEVELOPMENT
13 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN
13.1 INTRODUCTION
13.2 BIOLOGICAL/NATURAL SOURCES
13.2.1 ANIMAL-DERIVED
13.2.1.1 Established assay performance and broad availability to sustain use of animal-derived IVD raw materials
13.2.2 HUMAN-DERIVED
13.2.2.1 Clinical relevance and patient-like matrices to sustain demand for human-derived IVD raw materials
13.3 RECOMBINANT/SYNTHETIC SOURCES
13.3.1 E. COLI-EXPRESSED
13.3.1.1 Scalable production and strong suitability for non-glycosylated proteins to support E. coli-based recombinant IVD materials
13.3.2 CHO-EXPRESSED
13.3.2.1 Mammalian expression for structurally complex biomarkers to improve assay relevance and performance
13.3.3 CHEMICALLY SYNTHESIZED
13.3.3.1 Precisely defined composition and scalable manufacturing to expand the role of synthetic materials in IVD
13.4 OTHER SOURCES
14 IVD RAW MATERIALS MARKET, BY END USER
14.1 INTRODUCTION
14.2 IVD MANUFACTURERS
14.2.1 EXPANDING ASSAY PORTFOLIOS AND TIGHTER CONTROL OF CRITICAL COMPONENTS TO DRIVE RAW-MATERIAL CONSUMPTION
14.3 CONTRACT RESEARCH ORGANIZATIONS
14.3.1 INCREASING OUTSOURCING OF ASSAY DEVELOPMENT AND VALIDATION TO ACCELERATE IVD COMMERCIALIZATION
14.4 ACADEMIC & RESEARCH INSTITUTES
14.4.1 GROWING TRANSLATIONAL RESEARCH AND ASSAY DEVELOPMENT TO EXPAND CONSUMPTION OF SPECIALIZED IVD RAW MATERIALS
14.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.5.1 INTEGRATION OF DIAGNOSTICS INTO DRUG DEVELOPMENT TO INCREASE DEMAND FOR BIOMARKER AND ASSAY COMPONENTS
14.6 OTHER END USERS
15 IVD RAW MATERIALS MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 US
15.2.1.1 Increasing demand for advanced diagnostics and a mature reimbursement framework to drive market
15.2.2 CANADA
15.2.2.1 Rising disease prevalence and demand for early diagnoses drive market growth
15.3 EUROPE
15.3.1 GERMANY
15.3.1.1 Increasing investments in life sciences and advanced diagnostics to propel demand for IVD raw materials
15.3.2 UK
15.3.2.1 Rising adoption of genomic testing and advanced diagnostics to support demand growth
15.3.3 FRANCE
15.3.3.1 High healthcare expenditure and continued investment in genomic medicine to drive market
15.3.4 ITALY
15.3.4.1 Growing geriatric population and increasing burden of chronic diseases to boost demand for IVD raw materials
15.3.5 SPAIN
15.3.5.1 Increasing adoption of genomic testing and advanced diagnostics to support the market
15.3.6 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 CHINA
15.4.1.1 Growing focus on preventive care and localization of IVD raw materials to boost market
15.4.2 JAPAN
15.4.2.1 Increasing research investment and adoption of advanced diagnostics to support market growth
15.4.3 INDIA
15.4.3.1 Rising incidence of diabetes and cancer and increasing localization of IVD manufacturing to augment growth
15.4.4 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 INCREASING HEALTHCARE INVESTMENT, DISEASE BURDEN, AND EXPANSION OF DIAGNOSTIC ACCESS TO SUPPORT MARKET GROWTH
15.6 MIDDLE EAST & AFRICA
15.6.1 INCREASING HEALTHCARE INVESTMENT, PREVENTIVE SCREENING, AND DIAGNOSTIC INFRASTRUCTURE TO SUPPORT MARKET GROWTH
16 IVD RAW MATERIALS MARKET: VOLUME ANALYSIS
16.1 INTRODUCTION
16.2 GLOBAL: NAT BASED PCR EQUIPMENT SOLD, 2024–2031 (THOUSAND UNITS)
17 COMPETITIVE LANDSCAPE
17.1 INTRODUCTION
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN IVD RAW MATERIALS MARKET
17.3 REVENUE ANALYSIS, 2023–2025
17.4 MARKET SHARE ANALYSIS, 2025
17.4.1 THIRD-PARTY SUPPLIERS MARKET SHARE ANALYSIS, 2025
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
17.5.1 STARS
17.5.2 EMERGING LEADERS
17.5.3 PERVASIVE PLAYERS
17.5.4 PARTICIPANTS
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
17.5.5.1 Company footprint
17.5.5.2 Region footprint
17.5.5.3 Product type footprint
17.5.5.4 End-user footprint
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.6.1 PROGRESSIVE COMPANIES
17.6.2 RESPONSIVE COMPANIES
17.6.3 DYNAMIC COMPANIES
17.6.4 STARTING BLOCKS
17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.6.5.1 Detailed list of key startups/SMEs
17.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
17.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
17.7 COMPANY VALUATION & FINANCIAL METRICS
17.7.1 FINANCIAL METRICS
17.7.2 COMPANY VALUATION
17.8 BRAND/PRODUCT COMPARISON
17.9 COMPETITIVE SCENARIO
17.9.1 PRODUCT LAUNCHES & APPROVALS
17.9.2 DEALS
18 COMPANY PROFILES
18.1 KEY PLAYERS
18.1.1 MERCK KGAA
18.1.1.1 Business overview
18.1.1.2 Products offered
18.1.1.3 Recent developments
18.1.1.3.1 Product launches & approvals
18.1.1.3.2 Deals
18.1.1.4 MnM view
18.1.1.4.1 Key strengths
18.1.1.4.2 Strategic choices
18.1.1.4.3 Weaknesses and competitive threats
18.1.2 THERMO FISHER SCIENTIFIC
18.1.2.1 Business overview
18.1.2.2 Products offered
18.1.2.3 Recent developments
18.1.2.3.1 Product enhancements
18.1.2.3.2 Deals
18.1.2.4 MnM view
18.1.2.4.1 Key strengths
18.1.2.4.2 Strategic choices
18.1.2.4.3 Weaknesses & competitive threats
18.1.3 BIO-TECHNE CORPORATION
18.1.3.1 Business overview
18.1.3.2 Products & services offered
18.1.3.3 Recent developments
18.1.3.3.1 Product launches & approvals
18.1.3.3.2 Deals
18.1.3.4 MnM view
18.1.3.4.1 Key strengths
18.1.3.4.2 Strategic choices
18.1.3.4.3 Weaknesses & competitive threats
18.1.4 FAPON BIOTECH
18.1.4.1 Business overview
18.1.4.2 Products & services offered
18.1.4.3 Recent developments
18.1.4.3.1 Product launches & approvals
18.1.4.4 MnM view
18.1.4.4.1 Key strengths
18.1.4.4.2 Strategic choices
18.1.4.4.3 Weaknesses & competitive threats
18.1.5 MERIDIAN BIOSCIENCE
18.1.5.1 Business overview
18.1.5.2 Products offered
18.1.5.3 Recent developments
18.1.5.3.1 Product launches
18.1.5.3.2 Deals
18.1.5.4 MnM view
18.1.5.4.1 Key strengths
18.1.5.4.2 Strategic choices
18.1.5.4.3 Weaknesses & competitive threats
18.1.6 MEDIX BIOCHEMICA
18.1.6.1 Business overview
18.1.6.2 Products & services offered
18.1.6.3 Recent developments
18.1.6.3.1 Deals
18.1.6.3.2 Expansions
18.1.7 ROCHE CUSTOMBIOTECH
18.1.7.1 Business overview
18.1.7.2 Products & services offered
18.1.8 DANAHER CORPORATION
18.1.8.1 Business overview
18.1.8.2 Products & services offered
18.1.8.3 Recent developments
18.1.8.3.1 Deals
18.1.9 SARTORIUS AG
18.1.9.1 Business overview
18.1.9.2 Products offered
18.1.10 HYTEST LTD.
18.1.10.1 Business overview
18.1.10.2 Products offered
18.1.11 TOYOBO CO., LTD.
18.1.11.1 Business overview
18.1.11.2 Products offered
18.1.12 LGC BIOSEARCH TECHNOLOGIES
18.1.12.1 Business overview
18.1.12.2 Products offered
18.2 OTHER PLAYERS
18.2.1 BBI SOLUTIONS
18.2.2 SURMODICS IVD
18.2.3 AHLSTROM OYJ
18.2.4 BANGS LABORATORIES
18.2.5 SCRIPPS LABORATORIES, INC.
18.2.6 MIKROGEN GMBH
18.2.7 ADVANCED MICRODEVICES PVT. LTD.
18.2.8 SEKISUI DIAGNOSTICS
18.2.9 RANDOX LABORATORIES LTD.
18.2.10 HIMEDIA LABORATORIES
18.2.11 SINO BIOLOGICAL
18.2.12 BIOSYNTH
18.2.13 NEW ENGLAND BIOLABS, INC.
19 RESEARCH METHODOLOGY
19.1 RESEARCH DATA
19.2 SECONDARY DATA
19.2.1 LIST OF SECONDARY SOURCES
19.2.2 PRIMARY DATA
19.2.2.1 Key data from primary sources
19.2.2.2 Breakdown of primary interviews
19.3 MARKET SIZE ESTIMATION
19.3.1 TOTAL MARKET SIZE: IVD RAW MATERIALS MARKET
19.3.2 BOTTOM-UP APPROACH
19.3.2.1 Approach 2: Study of annual reports and investor presentations
19.3.2.2 Approach 3: Primary interviews
19.3.2.3 Growth forecast
19.3.3 TOP-DOWN APPROACH
19.4 DATA TRIANGULATION
19.5 RESEARCH ASSUMPTIONS
19.5.1 STUDY-RELATED ASSUMPTIONS
19.6 STUDY ASSUMPTIONS
19.6.1 GROWTH RATE ASSUMPTIONS
19.7 RESEARCH LIMITATIONS
19.8 RISK ASSESSMENT
20 APPENDIX
20.1 DISCUSSION GUIDE
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3 CUSTOMIZATION OPTIONS
20.4 RELATED REPORTS
20.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 RECENT INDICATORS SUPPORTING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
TABLE 2 RECENT INDUSTRY DEVELOPMENTS SUPPORTING RECOMBINANT BIOMOLECULE ADOPTION
TABLE 3 PORTER’S FIVE FORCES ANALYSIS: IMPACT ANALYSIS
TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 5 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 6 EUROPE: MACROECONOMIC INDICATORS
TABLE 7 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 8 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 9 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 10 IVD RAW MATERIALS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 11 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, BY REGION, 2024–2026 (USD)
TABLE 12 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, KEY PLAYER, 2024–2026 (USD)
TABLE 13 IMPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 14 EXPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 15 IVD RAW MATERIALS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 17 IVD RAW MATERIALS MARKET—KEY TECHNOLOGIES
TABLE 18 KEY PATENTS IN IVD RAW MATERIALS, 2023–2026
TABLE 19 KEY COMPANIES IMPLEMENTING AI IN IVD RAW MATERIALS MARKET
TABLE 20 US: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS
TABLE 21 CANADA: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS
TABLE 22 JAPAN: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS
TABLE 23 CHINA: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
TABLE 30 KEY BUYING CRITERIA, BY END USER
TABLE 31 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 32 IVD RAW MATERIALS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 33 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 34 ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 35 ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 RECOMBINANT ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 NORTH AMERICA: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 EUROPE: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 ASIA PACIFIC: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 52 ANTIGENS & PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 RECOMBINANT ANTIGENS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 NORTH AMERICA: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 EUROPE: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 ASIA PACIFIC: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 NATIVE PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 EUROPE: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 ASIA PACIFIC: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 CALIBRATORS & STANDARDS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 NORTH AMERICA: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 EUROPE: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 ASIA PACIFIC: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 69 ENZYMES & SUBSTRATES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 EUROPE: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 ASIA PACIFIC: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 DETECTION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 NORTH AMERICA: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 EUROPE: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 ASIA PACIFIC: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 AMPLIFICATION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 78 NORTH AMERICA: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 EUROPE: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 ASIA PACIFIC: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 SUBSTRATES & COENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 NORTH AMERICA: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 EUROPE: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 ASIA PACIFIC: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 PRIMERS & PROBES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 NORTH AMERICA: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 EUROPE: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ASIA PACIFIC: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 SYNTHETIC DNA/RNA MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 NORTH AMERICA: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 EUROPE: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 ASIA PACIFIC: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 99 BEADS & PARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 100 NORTH AMERICA: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 EUROPE: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 ASIA PACIFIC: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 MAGNETIC BEADS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 104 NORTH AMERICA: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 EUROPE: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 ASIA PACIFIC: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 LATEX BEADS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NORTH AMERICA: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 ASIA PACIFIC: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 GOLD NANOPARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 116 MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 NORTH AMERICA: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 EUROPE: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 ASIA PACIFIC: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 NITROCELLULOSE MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 EUROPE: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 NYLON & PVDF MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 125 NORTH AMERICA: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY,
2024–2031 (USD MILLION)
TABLE 126 EUROPE: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 ASIA PACIFIC: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 GLASS FIBER PADS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 129 NORTH AMERICA: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 EUROPE: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 ASIA PACIFIC: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 133 LABELS & DETECTION MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 ASIA PACIFIC: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 FLUORESCENT DYES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 CHEMILUMINESCENT LABELS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 NORTH AMERICA: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 EUROPE: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 ASIA PACIFIC: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 COLLOIDAL GOLD CONJUGATES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 146 NORTH AMERICA: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 EUROPE: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 ASIA PACIFIC: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 BUFFERS & DILUENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 150 NORTH AMERICA: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 EUROPE: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 ASIA PACIFIC: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 154 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 158 IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 CLINICAL CHEMISTRY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 167 NORTH AMERICA: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 EUROPE: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 ASIA PACIFIC: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 HEMATOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 NORTH AMERICA: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 EUROPE: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 ASIA PACIFIC: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 MICROBIOLOGY & CULTURE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 175 NORTH AMERICA: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 EUROPE: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 ASIA PACIFIC: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 COAGULATION TESTING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 179 NORTH AMERICA: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 EUROPE: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 ASIA PACIFIC: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 FLOW CYTOMETRY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 NORTH AMERICA: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 EUROPE: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185 ASIA PACIFIC: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 187 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 191 IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 196 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 EUROPE: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 EUROPE: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 208 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 EUROPE: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY REGION, 2024–2031 (USD MILLION)
TABLE 212 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 EUROPE: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY REGION, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 EUROPE: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 220 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221 EUROPE: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 224 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION)
TABLE 228 IN-HOUSE MANUFACTURING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 NORTH AMERICA: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 EUROPE: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 ASIA PACIFIC: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 THIRD-PARTY SUPPLY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 233 NORTH AMERICA: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 EUROPE: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 ASIA PACIFIC: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION)
TABLE 237 BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 BIOLOGICAL/NATURAL SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 239 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 ASIA PACIFIC: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 NORTH AMERICA: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 EUROPE: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 ASIA PACIFIC: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 247 NORTH AMERICA: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 EUROPE: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 ASIA PACIFIC: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 250 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 251 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 252 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 EUROPE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 ASIA PACIFIC: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 256 NORTH AMERICA: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 EUROPE: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 ASIA PACIFIC: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 260 NORTH AMERICA: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 EUROPE: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 ASIA PACIFIC: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 264 NORTH AMERICA: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 EUROPE: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 266 ASIA PACIFIC: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 OTHER IVD RAW MATERIAL SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 268 NORTH AMERICA: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 EUROPE: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 ASIA PACIFIC: IVD RAW MATERIAL OTHER SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 272 IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 273 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 EUROPE: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 IVD RAW MATERIALS MARKET FOR CROS, BY REGION, 2024–2031 (USD MILLION)
TABLE 277 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 EUROPE: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280 IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 281 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 EUROPE: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 285 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 EUROPE: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 289 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 293 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 295 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 296 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 299 NORTH AMERICA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 300 NORTH AMERICA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 301 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 303 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 304 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION)
TABLE 305 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION)
TABLE 306 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 307 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 1 RECENT INDICATORS SUPPORTING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
TABLE 2 RECENT INDUSTRY DEVELOPMENTS SUPPORTING RECOMBINANT BIOMOLECULE ADOPTION
TABLE 3 PORTER’S FIVE FORCES ANALYSIS: IMPACT ANALYSIS
TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 5 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 6 EUROPE: MACROECONOMIC INDICATORS
TABLE 7 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 8 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 9 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 10 IVD RAW MATERIALS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 11 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, BY REGION, 2024–2026 (USD)
TABLE 12 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, KEY PLAYER, 2024–2026 (USD)
TABLE 13 IMPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 14 EXPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 15 IVD RAW MATERIALS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 17 IVD RAW MATERIALS MARKET—KEY TECHNOLOGIES
TABLE 18 KEY PATENTS IN IVD RAW MATERIALS, 2023–2026
TABLE 19 KEY COMPANIES IMPLEMENTING AI IN IVD RAW MATERIALS MARKET
TABLE 20 US: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS
TABLE 21 CANADA: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS
TABLE 22 JAPAN: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS
TABLE 23 CHINA: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
TABLE 30 KEY BUYING CRITERIA, BY END USER
TABLE 31 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 32 IVD RAW MATERIALS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 33 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 34 ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 35 ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 RECOMBINANT ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 NORTH AMERICA: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 EUROPE: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 ASIA PACIFIC: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 52 ANTIGENS & PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 RECOMBINANT ANTIGENS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 NORTH AMERICA: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 EUROPE: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 ASIA PACIFIC: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 NATIVE PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 EUROPE: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 ASIA PACIFIC: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 CALIBRATORS & STANDARDS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 NORTH AMERICA: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 EUROPE: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 ASIA PACIFIC: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 69 ENZYMES & SUBSTRATES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 EUROPE: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 ASIA PACIFIC: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 DETECTION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 NORTH AMERICA: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 EUROPE: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 ASIA PACIFIC: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 AMPLIFICATION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 78 NORTH AMERICA: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 EUROPE: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 ASIA PACIFIC: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 SUBSTRATES & COENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 NORTH AMERICA: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 EUROPE: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 ASIA PACIFIC: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 PRIMERS & PROBES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 NORTH AMERICA: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 EUROPE: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ASIA PACIFIC: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 SYNTHETIC DNA/RNA MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 NORTH AMERICA: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 EUROPE: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 ASIA PACIFIC: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 99 BEADS & PARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 100 NORTH AMERICA: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 EUROPE: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 ASIA PACIFIC: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 MAGNETIC BEADS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 104 NORTH AMERICA: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 EUROPE: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 ASIA PACIFIC: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 LATEX BEADS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NORTH AMERICA: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 ASIA PACIFIC: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 GOLD NANOPARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 116 MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 NORTH AMERICA: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 EUROPE: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 ASIA PACIFIC: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 NITROCELLULOSE MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 EUROPE: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 NYLON & PVDF MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 125 NORTH AMERICA: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY,
2024–2031 (USD MILLION)
TABLE 126 EUROPE: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 ASIA PACIFIC: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 GLASS FIBER PADS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 129 NORTH AMERICA: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 EUROPE: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 ASIA PACIFIC: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 133 LABELS & DETECTION MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 ASIA PACIFIC: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 FLUORESCENT DYES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 CHEMILUMINESCENT LABELS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 NORTH AMERICA: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 EUROPE: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 ASIA PACIFIC: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 COLLOIDAL GOLD CONJUGATES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 146 NORTH AMERICA: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 EUROPE: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 ASIA PACIFIC: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 BUFFERS & DILUENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 150 NORTH AMERICA: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 EUROPE: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 ASIA PACIFIC: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 154 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 158 IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 CLINICAL CHEMISTRY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 167 NORTH AMERICA: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 EUROPE: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 ASIA PACIFIC: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 HEMATOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 NORTH AMERICA: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 EUROPE: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 ASIA PACIFIC: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 MICROBIOLOGY & CULTURE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 175 NORTH AMERICA: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 EUROPE: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 ASIA PACIFIC: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 COAGULATION TESTING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 179 NORTH AMERICA: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 EUROPE: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 ASIA PACIFIC: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 FLOW CYTOMETRY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 NORTH AMERICA: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 EUROPE: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185 ASIA PACIFIC: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 187 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 191 IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 196 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 EUROPE: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 EUROPE: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 208 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 EUROPE: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY REGION, 2024–2031 (USD MILLION)
TABLE 212 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 EUROPE: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY REGION, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 EUROPE: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 220 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221 EUROPE: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 224 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION)
TABLE 228 IN-HOUSE MANUFACTURING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 NORTH AMERICA: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 EUROPE: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 ASIA PACIFIC: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 THIRD-PARTY SUPPLY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 233 NORTH AMERICA: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 EUROPE: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 ASIA PACIFIC: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION)
TABLE 237 BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 BIOLOGICAL/NATURAL SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 239 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 ASIA PACIFIC: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 NORTH AMERICA: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 EUROPE: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 ASIA PACIFIC: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 247 NORTH AMERICA: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 EUROPE: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 ASIA PACIFIC: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 250 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 251 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 252 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 EUROPE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 ASIA PACIFIC: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 256 NORTH AMERICA: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 EUROPE: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 ASIA PACIFIC: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 260 NORTH AMERICA: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 EUROPE: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 ASIA PACIFIC: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 264 NORTH AMERICA: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 EUROPE: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 266 ASIA PACIFIC: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 OTHER IVD RAW MATERIAL SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 268 NORTH AMERICA: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 EUROPE: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 ASIA PACIFIC: IVD RAW MATERIAL OTHER SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 272 IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 273 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 EUROPE: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 IVD RAW MATERIALS MARKET FOR CROS, BY REGION, 2024–2031 (USD MILLION)
TABLE 277 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 EUROPE: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280 IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 281 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 EUROPE: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 285 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 EUROPE: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 289 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 293 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 295 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 296 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 299 NORTH AMERICA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 300 NORTH AMERICA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 301 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 303 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 304 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION)
TABLE 305 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION)
TABLE 306 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 307 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 IVD RAW MATERIALS MARKET SEGMENTATION
FIGURE 2 REGIONAL SCOPE
FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS
FIGURE 4 GLOBAL IVD RAW MATERIALS MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IVD RAW MATERIALS MARKET, 2023–2026
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF IVD RAW MATERIALS MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN IVD RAW MATERIALS MARKET, 2025
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 9 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
FIGURE 10 ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 11 IMMUNOASSAY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 12 INFECTIOUS DISEASES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13 IN-HOUSE MANUFACTURING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 BIOLOGICAL/NATURAL SOURCES TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 15 IVD MANUFACTURERS SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 17 IVD RAW MATERIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 18 IVD RAW MATERIALS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 19 IVD RAW MATERIALS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 20 IVD RAW MATERIALS MARKET: VALUE CHAIN ANALYSIS
FIGURE 21 IVD RAW MATERIALS MARKET: ECOSYSTEM ANALYSIS
FIGURE 22 IVD RAW MATERIALS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 23 DEALS & FUNDING ACTIVITIES IN IVD RAW MATERIALS MARKET
FIGURE 24 PATENT ANALYSIS FOR IVD RAW MATERIALS, JANUARY 2016–DECEMBER 2025
FIGURE 25 MARKET POTENTIAL OF AI IN IVD RAW MATERIALS MARKET
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
FIGURE 27 KEY BUYING CRITERIA, BY END USER
FIGURE 28 NORTH AMERICA: IVD RAW MATERIALS MARKET SNAPSHOT
FIGURE 29 ASIA PACIFIC: IVD RAW MATERIALS MARKET SNAPSHOT
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN IVD RAW MATERIALS MARKET, 2023–2025 (USD MILLION)
FIGURE 31 IVD RAW MATERIALS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
FIGURE 32 IVD RAW MATERIALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 33 IVD RAW MATERIALS MARKET: COMPANY FOOTPRINT
FIGURE 34 IVD RAW MATERIALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 35 EV/EBITDA OF KEY VENDORS
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 37 IVD RAW MATERIALS MARKET: BRAND/PRODUCT COMPARISON FOR RECOMBINANT HUMAN IL-6 PROTEIN
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 40 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025)
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 43 SARTORIUS AG: COMPANY SNAPSHOT (2025)
FIGURE 44 TOYOBO CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45 LGC BIOSEARCH TECHNOLOGIES: COMPANY SNAPSHOT (2025)
FIGURE 46 RESEARCH DESIGN
FIGURE 47 KEY DATA FROM SECONDARY SOURCES
FIGURE 48 LIST OF PRIMARY SOURCES
FIGURE 49 KEY INDUSTRY INSIGHTS
FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 51 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
FIGURE 52 CAGR PROJECTIONS
FIGURE 53 TOP-DOWN APPROACH
FIGURE 54 DATA TRIANGULATION
FIGURE 55 PARAMETRIC ASSUMPTIONS
FIGURE 1 IVD RAW MATERIALS MARKET SEGMENTATION
FIGURE 2 REGIONAL SCOPE
FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS
FIGURE 4 GLOBAL IVD RAW MATERIALS MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IVD RAW MATERIALS MARKET, 2023–2026
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF IVD RAW MATERIALS MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN IVD RAW MATERIALS MARKET, 2025
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 9 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
FIGURE 10 ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 11 IMMUNOASSAY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 12 INFECTIOUS DISEASES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13 IN-HOUSE MANUFACTURING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 BIOLOGICAL/NATURAL SOURCES TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 15 IVD MANUFACTURERS SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 17 IVD RAW MATERIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 18 IVD RAW MATERIALS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 19 IVD RAW MATERIALS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 20 IVD RAW MATERIALS MARKET: VALUE CHAIN ANALYSIS
FIGURE 21 IVD RAW MATERIALS MARKET: ECOSYSTEM ANALYSIS
FIGURE 22 IVD RAW MATERIALS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 23 DEALS & FUNDING ACTIVITIES IN IVD RAW MATERIALS MARKET
FIGURE 24 PATENT ANALYSIS FOR IVD RAW MATERIALS, JANUARY 2016–DECEMBER 2025
FIGURE 25 MARKET POTENTIAL OF AI IN IVD RAW MATERIALS MARKET
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
FIGURE 27 KEY BUYING CRITERIA, BY END USER
FIGURE 28 NORTH AMERICA: IVD RAW MATERIALS MARKET SNAPSHOT
FIGURE 29 ASIA PACIFIC: IVD RAW MATERIALS MARKET SNAPSHOT
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN IVD RAW MATERIALS MARKET, 2023–2025 (USD MILLION)
FIGURE 31 IVD RAW MATERIALS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
FIGURE 32 IVD RAW MATERIALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 33 IVD RAW MATERIALS MARKET: COMPANY FOOTPRINT
FIGURE 34 IVD RAW MATERIALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 35 EV/EBITDA OF KEY VENDORS
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 37 IVD RAW MATERIALS MARKET: BRAND/PRODUCT COMPARISON FOR RECOMBINANT HUMAN IL-6 PROTEIN
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 40 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025)
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 43 SARTORIUS AG: COMPANY SNAPSHOT (2025)
FIGURE 44 TOYOBO CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45 LGC BIOSEARCH TECHNOLOGIES: COMPANY SNAPSHOT (2025)
FIGURE 46 RESEARCH DESIGN
FIGURE 47 KEY DATA FROM SECONDARY SOURCES
FIGURE 48 LIST OF PRIMARY SOURCES
FIGURE 49 KEY INDUSTRY INSIGHTS
FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 51 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
FIGURE 52 CAGR PROJECTIONS
FIGURE 53 TOP-DOWN APPROACH
FIGURE 54 DATA TRIANGULATION
FIGURE 55 PARAMETRIC ASSUMPTIONS
